WuXi partnership to bring genomic profiling to Chinese clinical trials

By Zachary Brennan

- Last updated on GMT

Industry sees rapid increases in demand for molecular profiling in China
Industry sees rapid increases in demand for molecular profiling in China

Related tags Medicine Wuxi

CRO WuXi PharmaTech is collaborating with Foundation Medicine to provide genomic profiling to biopharma companies conducting clinical trials in China.

Under the agreement, Foundation Medicine will license and enable WuXi to perform the laboratory component of Foundation Medicine's FoundationOne assay at the WuXi Genome Center in Shanghai. Financial terms of the collaboration are not being disclosed.

FoundationOne is a genomic profile that helps physicians make treatment decisions for patients with cancer by identifying the molecular growth drivers of their cancers and helping oncologists match them with relevant targeted therapeutic options.

Dai Jialing, public relations director for WuXi, told Outsourcing-Pharma.com, “WuXi has seen rapidly increasing demand for molecular profiling services from biopharmaceutical companies as they scale up R&D operations and early development activities in the region​.”   

Foundation Medicine will offer China-based products and services to global biopharmaceutical partners to support their clinical research and development efforts in China.   

The partnership, along with WuXi’s recent acquisition of DMPK/ADME service provider XenoBiotic​ Laboratories, shows the company is looking to expand and diversify beyond the manufacturing services​ driving its bottom line. 

"China is poised to become the second-largest pharmaceutical market within the next few years​," said Ge Li, chairman and CEO of WuXi. "We are pleased to partner with Foundation Medicine, the recognized global leader in comprehensive genomic profiling and a trusted partner of our customers, to provide best-in-class genomic testing to support targeted oncology therapeutic development in China​."

Foundation Medicine is helping more than 20 biopharma companies provide genomic profiling, including in more than 100 studies in 2014.  Partners include AstraZeneca, Eisai, Johnson & Johnson, Novartis and Sanofi.

Michael Pellini, president and CEO of Foundation Medicine added, "The development and use of targeted therapies and comprehensive diagnostic tests in oncology are expected to grow significantly in China. WuXi's leadership position in China makes WuXi an ideal partner​."

Related news

Show more

Related products

show more

Using Define-XML to build more efficient studies

Using Define-XML to build more efficient studies

Content provided by Formedix | 14-Nov-2023 | White Paper

It is commonly thought that Define-XML is simply a dataset descriptor: a way to document what datasets look like, including the names and labels of datasets...

Why should you use clinical trial technology?

Why should you use clinical trial technology?

Content provided by Formedix | 01-Nov-2023 | White Paper

New, innovative clinical trial technology is helping to revolutionize the research landscape. COVID-19 demonstrated that clinical trials can be run much...

Related suppliers